Wilfrid Sellars

BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rare natural history study of patients living with inherited retinal diseases

Retrieved on: 
Monday, March 25, 2024
Retina, Research, Gene, Development, IRD, Leber congenital amaurosis, Retinitis pigmentosa, Paratriathlon, Patient, Bayer, Foundation Fighting Blindness, Visual impairment, University, Wilfrid Sellars, Senior, IND, Therapy, IPSC, Usher syndrome, B cell, Pharmaceutical industry

The new cohort will include patients living with IRDs caused by mutations in multiple genes.

Key Points: 
  • The new cohort will include patients living with IRDs caused by mutations in multiple genes.
  • “BlueRock is developing a pipeline of cell therapies that we believe has great potential for restoring vision in people living with blindness caused by retinal disease,” said Ahmed Enayetallah, Senior Vice President and Head of Development for BlueRock Therapeutics.
  • Primary photoreceptor diseases are a subgroup of inherited retinal diseases that includes retinitis pigmentosa and cone- rod dystrophies.
  • OpCT-001 aims to restore vision loss caused by these diseases by replacing degenerated tissue in the retina with functional cells.

Piedmont Lithium Appoints New Board Director

Retrieved on: 
Monday, March 18, 2024
Alternative Vehicles, Fuels, EV, Electric Vehicles, Automotive, Chemicals, Plastics, Automotive Manufacturing, Alternative Energy, Manufacturing, Energy, Mining, Minerals, Natural Resources, Lithium, Piedmont Lithium, Organization, Chair, RTI, Growth, National Space Council, Executive, ALL, History, ASX, PLL, Transport, University, Wilfrid Sellars, RTI International Metals, NASA, Multimedia, AIM, Management

Piedmont Lithium (“Piedmont” or the “Company”) (Nasdaq: PLL; ASX: PLL), a leading global supplier of lithium resources critical to the U.S. electric vehicle (“EV”) supply chain, today announced the appointment of Dawne Hickton to the Board of Directors (“Board”), effective March 14, 2024.

Key Points: 
  • Piedmont Lithium (“Piedmont” or the “Company”) (Nasdaq: PLL; ASX: PLL), a leading global supplier of lithium resources critical to the U.S. electric vehicle (“EV”) supply chain, today announced the appointment of Dawne Hickton to the Board of Directors (“Board”), effective March 14, 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240318562526/en/
    “We are pleased to welcome Dawne to Piedmont’s Board,” said Jeff Armstrong, Chairman of the Company’s Board of Directors.
  • Piedmont Lithium Inc. (Nasdaq: PLL; ASX: PLL) is developing a world-class, multi-asset, integrated lithium business focused on enabling the transition to a net zero world and the creation of a clean energy economy in North America.
  • Our projects include our Carolina Lithium and Tennessee Lithium projects in the United States and partnerships in Quebec with Sayona Mining (ASX: SYA) and in Ghana with Atlantic Lithium (AIM: ALL; ASX: A11).

New Practice Guideline Co-Led by Penn Dental Medicine Details Dental Pain Management Strategies

Retrieved on: 
Wednesday, March 13, 2024
Dental care, JADA, Dentistry, Associate, Patient, Naproxen, Nonsteroidal anti-inflammatory drug, University, Paracetamol, American Dental Association, Wilfrid Sellars, Prescription, Risk, Toothache, Analgesic, Pain, Ibuprofen, Guideline

PHILADELPHIA, March 13, 2024 /PRNewswire/ -- A new clinical practice guideline for managing acute dental pain in adolescents and adults has been released, recommending nonsteroidal anti-inflammatory drugs (NSAIDs) taken alone or with acetaminophen as first-line treatments for managing short-term dental pain.

Key Points: 
  • PHILADELPHIA, March 13, 2024 /PRNewswire/ -- A new clinical practice guideline for managing acute dental pain in adolescents and adults has been released, recommending nonsteroidal anti-inflammatory drugs (NSAIDs) taken alone or with acetaminophen as first-line treatments for managing short-term dental pain.
  • The guideline was developed by Penn Dental Medicine's Center for Integrative Global Oral Health (CIGOH) , the American Dental Association (ADA), and the University of Pittsburgh School of Dental Medicine.
  • Dr. Alonso Carrasco-Labra, Associate Professor and Director of the Cochrane Oral Health Collaborating Center at Penn Dental Medicine, and Olivia Urquhart, an epidemiologist and instructor within CIGOH, co-led its development.
  • This is the second of two guidelines on acute dental pain management from this research team.

NMDP Awards 25th Annual ‘Amy Scholars’ Grant, Furthering Post-Transplant Research

Retrieved on: 
Wednesday, March 6, 2024
Bone marrow, Senior, Doctor of Philosophy, HCT, Research, Hematology, Graft-versus-host disease, Physician, Partnership, Data, University, Risk assessment, NMDP, Nursing, Patient, Disease, McGinn, DRS, Health equity, Laboratory, Buchbinder, Wilfrid Sellars, Pharmaceutical industry

Cieri and Sacirbegovic in their research efforts to improve the lives of those battling blood cancers and blood disorders.

Key Points: 
  • Cieri and Sacirbegovic in their research efforts to improve the lives of those battling blood cancers and blood disorders.
  • We are especially grateful to the Moore family, who generously funded the Amy Scholars Research Program in 2024,” said Joy King, Chief Advancement Officer, NMDP, and Executive Director, NMDP.
  • Since 1998, NMDP has invested more than $12 million, funding 51 early-career investigators and helping them develop research portfolios and establish their laboratories.
  • “For years, we have supported groundbreaking research by collaborating with an extensive network of physicians and scientists in impacting outcomes.

Spencer Fane Enters Nation’s Second Largest Legal Market with Patent Litigation Group

Retrieved on: 
Wednesday, February 28, 2024
Wake Forest University, Metallurgy, IAM, University, United States district court, International trade, Culture, District court, West Virginia University, Invention, Smartphone, Virginia University, Patent, University of Cincinnati, Intellectual property, Law, IP, Juris, Telecommunications, Chemical engineering, Semiconductor, Justice, Robotics, Software, Wilfrid Sellars

The trio joins the firm’s growing Intellectual Property practice while also giving Spencer Fane a foothold in the second-largest legal market in the U.S.

Key Points: 
  • The trio joins the firm’s growing Intellectual Property practice while also giving Spencer Fane a foothold in the second-largest legal market in the U.S.
  • The group joins a Spencer Fane IP team that possesses both the technical knowledge and legal experience necessary to protect inventors, entrepreneurs, and businesses of all sizes.
  • She has litigated patent cases for over 20 years, including as co-lead counsel in over ten lawsuits that went to trial.
  • Holley has managed all aspects of patent litigation including pre-filing diligence, claim construction, fact and expert discovery, dispositive motions, and trial.

SEC to Host Law School Summit Highlighting Need for Investor Access to Legal Counsel

Retrieved on: 
Friday, February 2, 2024
Northwestern University, Student, Pace University, RSVP, OIEA, Wilfrid Sellars, University School, Cornell Law School, Law school, Drexel University, University, Minority, Financial adviser

For the first time, the list of Summit invitees includes law schools without investor advocacy clinics, many of which are located in areas of the U.S. where free legal services for investors are scarce.

Key Points: 
  • For the first time, the list of Summit invitees includes law schools without investor advocacy clinics, many of which are located in areas of the U.S. where free legal services for investors are scarce.
  • “Investors who cannot afford private counsel are significantly disadvantaged in arbitration or litigation with their financial professionals,” said SEC Ombuds Stacy Puente.
  • The Summit will feature remarks from the SEC Chair, SEC Commissioners, Division Directors, the Investor Advocate, and the Director of FINRA Dispute Resolution Services.
  • Participating law school clinics include Benjamin N. Cardozo School of Law, Cornell University Law School, Fordham University School of Law, Howard University School of Law, Northwestern University Pritzker School of Law, Elizabeth Haub School of Law at Pace University, St. John’s University School of Law, Seton Hall University School of Law, University of Miami School of Law, and the University of Pittsburgh School of Law.

The Advanced Leadership Institute and Carnegie Mellon University Announce The 2024 Cohort of The Executive Leadership Academy

Retrieved on: 
Friday, January 26, 2024
Chief security officer, CNX, PNC, Onome, Pittsburgh Regional Transit, Dollar Bank, University of Pittsburgh, Federal Railroad Administration, Kelly Russell, Corporation, Associate, Diversity, Duquesne Light Company, City, Community engagement, Mathematical sciences, University, Cohort, Carnegie Mellon University, Workplace, PPG, Mamadou, Medicine, Division, Culture, CMU, Community development, UPMC, Leadership Academy, Organization, Wilfrid Sellars, FedEx Ground, Management

PITTSBURGH, Jan. 26, 2024 /PRNewswire/ -- The Advanced Leadership Institute (TALI) and Carnegie Mellon University Tepper School of Business (CMU) are pleased to announce the 2024 Executive Leadership Academy cohort.

Key Points: 
  • PITTSBURGH, Jan. 26, 2024 /PRNewswire/ -- The Advanced Leadership Institute (TALI) and Carnegie Mellon University Tepper School of Business (CMU) are pleased to announce the 2024 Executive Leadership Academy cohort.
  • Since 2019, TALI has engaged CMU Tepper Executive Education to assist with developing and delivering content that educates and expands diverse leadership from Pittsburgh through TALI's signature program — the Executive Leadership Academy.
  • The 2024 Executive Leadership Academy cohort furthers our mission and vision," says Evan Frazier, President and CEO, The Advanced Leadership Institute.
  • TALI and CMU will welcome the new cohort at the 2024 Executive Leadership Academy Kick-Off Program and Reception on January 26, 2024.

Dr. Michael Hilton, Renowned Emergency Medicine Expert, Expands Services to Enhance Private Medical Practices

Retrieved on: 
Thursday, January 25, 2024
Assistant, Patient, HIPAA, Health, CLIA, Medical director, Emergency medicine, University, DEA, OSHA, Environment, Nursing care plan, Medicine, Wilfrid Sellars, Medical device

NEW YORK, Jan. 25, 2024 /PRNewswire/ -- Dr. Michael Hilton , a distinguished figure in Emergency Medicine, is taking a pioneering step towards fortifying private medical practices with his expanded range of services.

Key Points: 
  • NEW YORK, Jan. 25, 2024 /PRNewswire/ -- Dr. Michael Hilton , a distinguished figure in Emergency Medicine, is taking a pioneering step towards fortifying private medical practices with his expanded range of services.
  • With a commitment to elevating medical standards, Dr. Michael Hilton is now available to consult with private medical practices in the New York area.
  • As part of his expanded services, Dr. Michael Hilton is dedicated to assisting private medical practices in setting up Physician Office CLIA-waived and CLIA-Moderate Complexity Labs.
  • In the realm of private medical practices, Dr. Michael Hilton emerges as a beacon of expertise, guiding practitioners towards excellence in patient care, regulatory adherence, and operational efficiency.

DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay

Retrieved on: 
Tuesday, January 16, 2024
Oncology, Health, Genetics, Health Technology, Clinical Trials, Biotechnology, Patient, Melanoma, NPV, TERT, University, PRAME, Wilfrid Sellars, Biopsy, DMT, Pharmaceutical industry

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that it will discontinue the optional TERT promoter mutation add-on assay for its DermTech Melanoma Test (DMT) effective March 1, 2024.

Key Points: 
  • DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced that it will discontinue the optional TERT promoter mutation add-on assay for its DermTech Melanoma Test (DMT) effective March 1, 2024.
  • Multiple studies, including the Company’s recently completed Trust 2 Study, demonstrated the DMT’s negative predictive value (NPV) to be 99% or higher.
  • A high NPV for a rule-out test provides assurance to clinicians and patients that a suspicious pigmented lesion which tests negative is unlikely to be a melanoma.
  • The TERT promoter mutation assay was offered as an optional add-on to the foundational gene expression assay for LINC00518 and PRAME based on initial validation data suggesting it conferred a modest increase in NPV.

RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer

Retrieved on: 
Thursday, December 21, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Associate, Cougar, Wilfrid Sellars, Cholangiocarcinoma, Blood, Hematology, NDA, MD, Radiology, Clinical trial, Glomus tumor, University, Pancreatic cancer, University of Oklahoma, Durvalumab, Interventional radiology, Patient, Safety, Senior, Medical imaging

The CouGar Trial will evaluate RenovoGem in bile duct cancer, specifically unresectable locally advanced extrahepatic cholangiocarcinoma (eCCA).

Key Points: 
  • The CouGar Trial will evaluate RenovoGem in bile duct cancer, specifically unresectable locally advanced extrahepatic cholangiocarcinoma (eCCA).
  • “We are pleased to engage our first clinical site for our second pivotal clinical trial.
  • The CouGar Trial marks an important milestone for RenovoRx as we expand our clinical pipeline for RenovoGem into bile duct cancer, a difficult-to-treat solid tumor cancer,” said Leesa Gentry, Senior Vice President of Clinical Operations at RenovoRx.
  • Oklahoma University (OU) Health is the first clinical site for the CouGar study.